*Date: 2023-10-28*
*Time: 15:54* 


### Classification

| Characteristics        | Type 1 Endometrial Carcinoma | Type 2 Endometrial Carcinoma                                                                                                    |
| ---------------------- | ---------------------------- | ------------------------------------------------------------------------------------------------------------------------------- |
| **Epidemiology**       | 80%                          | 20%                                                                                                                             |
| Age distribution       | Commonly [[Perimenopause]]   | Older patients                                                                                                                  |
| Risk factor            | [[Estrogen exposure]]        |                                                                                                                                 |
| **Initial lesion**     | [[Endometrial hyperplasia]]  | [[Endometrial atrophy]]<br>                                                                                                     |
| **Pathology**          | Endometrioid or mucinous     | Grade 3 Endometrioid, Adenocarcinoma<br>Non-endometrioid subtypes: Serous, clear cell, squamous, transitional, undifferentiated |
| **Estrogen receptors** | Positive: SERMs usable       | Not usable, hormone negative cancers, like some breast cancers; have bad prognosis                                              |
| **Mutation**           | [[PTEN]] or KRAS             | Mutation in [[p53]]                                                                                                             |
| Prognosis              | Good                         | poor                                                                                                                            |
| Invasion               | Superficial                  | Deep                                                                                                                            |
estrogen and progesterone receptor expression, vimentin positivity, weak to negative p16
### Presentation
- [[Postmenopausal bleeding]]
- Heavy prolonged bleeding
- Hematometra in some patients with cervical stenosis
- Pyometra: purulent vaginal discharge
### Diagnostics
- Transvaginal USG
	- [[Endometrial sampling]] is #ioc if USG finding suspicious or repeat bleeding in PMB
	- [[Fractional curettage]] with [[Hysteroscopy]] guidance under [[anesthesia]] is #gold-standard  for endometrial investigation

| Thickness                         | Next step                 |
| --------------------------------- | ------------------------- |
| > 4 mm                            | [[Endometrial biopsy]]    |
| â‰¤ 4 cm                            | Not routinely recommended |
| Endometrial lining not visualized | Endometrial biopsy        |

- Genetic studies
	- [[Lynch syndrome]] testing to be done in all women with endometrial cancer
	- Other mutations
		- Hormone receptors
		- [[BRCA1/BRCA2]]
		- [[Cowden disease]]
- [[Endometrial carcinoma staging]] 
	- MRI 
	- CT- chest, abdomen and pelvis
	- PET-CT scan
### Staging


### Management
- TVUS
- Fertility: [[Hysterectomy]] with BL Salpingo-oophorectomy
- Patients wishing to preserve fertility
	- Uterine preservation in early-stage 
	- [[Progestin therapy]]

### Complications
- [[Pyometra]]